Astellas Gene Therapies is closing its San Francisco biomanufacturing facility, shifting gene therapy manufacturing to North Carolina, cutting at least 17 employees and affecting dozens more. #biopharma #layoffs #genetherapy #biospace https://hubs.li/Q02Np0Pz0
BioSpace
Internet News
West Des Moines, Iowa 116,368 followers
The leading source for biopharma news and jobs. Connecting industry pioneers with talented professionals.
About us
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
- Website
-
http://www.biospace.com/
External link for BioSpace
- Industry
- Internet News
- Company size
- 11-50 employees
- Headquarters
- West Des Moines, Iowa
- Type
- Privately Held
- Founded
- 1985
- Specialties
- biotech jobs, pharma jobs, biotech news, pharma news, and life sciences news
Locations
-
Primary
3001 Westown Pkwy
#101
West Des Moines, Iowa 50266, US
Employees at BioSpace
-
Greg Slabodkin
-
Dr. D. Martin Alexander Gershon, MD, JD, MPH
AI & Digital Health Innovation Keynote•Linkedin “Top Voice” Venture Capital, Entrepreneurship, & Fundraising•Techstars Sr EIR•Goldman…
-
Angela Gabriel
Content Manager (Life Sciences Careers) at BioSpace
-
Lori Ellis (Katz)
Head of Insights
Updates
-
Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial. #pharma #biospace https://hubs.li/Q02Np3-N0
Bayer’s Kidney Disease Drug Kerendia Reduces Cardiovascular Risk by 16%
-
On Friday, the FDA authorized the company’s updated COVID-19 vaccine as the third booster option for Americans this fall. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024. #vaccine #COVID-19 #pharma #biospace https://hubs.li/Q02Np2s20
FDA Authorizes New Mpox Vaccine, COVID-19 Booster
biospace.com
-
The BTK inhibitor showed promise in non-relapsing secondary progressive multiple sclerosis but not relapsing MS. The company said it plans to apply for approval for the former “as soon as possible.” #pharma #MS #biospace https://hubs.li/Q02Np02r0
Sanofi’s Tolebrutinib Misses Two of Three Late-Stage Multiple Sclerosis Readouts
biospace.com
-
Novo Nordisk's continuing supply problems for semaglutide come as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures. #pharma #biospace https://hubs.li/Q02Np3XB0
Novo’s Ozempic to Remain in Shortage Into Q4 as Supply Woes Continue
biospace.com
-
Unlike Pfizer/BioNTech SE and Moderna, Novavaxdoes not use mRNA technology for its COVID-19 vaccine, instead opting for a recombinant version of the virus’ spike protein to elicit protection. #mRNA #COVID-19 #vaccine #biospace https://hubs.li/Q02NnVLQ0
Novavax Catches Up to Competitors With FDA Approval for Updated COVID-19 Boosters
biospace.com
-
The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment. #pharma #biospace https://hubs.li/Q02NnZZH0
Dyne Touts ‘Unprecedented’ Dystrophin Expression in Phase I/II DMD Trial for Exon-Skipping Therapy
biospace.com
-
The FDA's inertia and bureaucratic roadblocks are throttling hope for millions of patients. A new center of excellence would provide a solution. #FDA #biopharma #biospace https://hubs.li/Q02NnpK70
Opinion: The FDA Needs a Dedicated ‘Center for Rare Diseases’
biospace.com
-
The FDA has three regulatory milestones in the next two weeks, including a decision on a subcutaneous formulation of an effective multiple sclerosis therapy. #FDA #pharma #biospace https://hubs.li/Q02NnbRq0
FDA Action Alert: Travere, Avadel and Roche
biospace.com
-
With gene therapies by REGENXBIO and AbbVie, Adverum and others in mid- or late-stage trials, this therapeutic class could soon be an option for this common cause of blindness in the elderly. #rarediseases #genetherapy #biospace https://hubs.li/Q02Nnq8-0
Beyond Rare Disease: Wet AMD Gene Therapy Could Reach Millions
biospace.com